Summary of Orchestra BioMed FY Conference Call Company Overview - **Company**: Orchestra BioMed (NasdaqGM:OBIO) - **Focus**: Biomedical innovation with two pivotal stage cardiovascular programs: - **Virtue Sirolimus AngioInfusion Balloon** for coronary artery disease - **Atrioventricular Interval Modulation (AVIM) therapy** for hypertensive heart disease in high-risk patients, partnered with Medtronic [7][36] Key Programs and Developments Virtue Sirolimus AngioInfusion Balloon - **Current Status**: Enrolling pivotal trials, with expectations to finish the BACKBEAT trial this year and data anticipated shortly thereafter [8] - **Market Potential**: Positioned in an almost $8 billion market, with a paradigm shift from drug-eluting stents to drug-eluting balloons [18][19] - **Competitive Landscape**: Currently, only Boston Scientific has a commercial coronary drug-coated balloon in the U.S. [18] - **Clinical Advantage**: Virtue aims to deliver better clinical results with a proprietary drug delivery method that encapsulates sirolimus, leading to significantly higher drug levels compared to existing products [25][26] Atrioventricular Interval Modulation (AVIM) Therapy - **Trial Progress**: Enrollment is accelerating with over 100 sites engaged, and protocol changes have improved participation [38] - **Therapeutic Impact**: AVIM therapy shows immediate blood pressure reduction in patients, with significant double-digit drops observed [40][41] - **Market Opportunity**: Estimated 1 million patients worldwide receiving pacemakers annually could benefit from AVIM therapy [42] - **Regulatory Path**: Medtronic is responsible for regulatory and manufacturing aspects, with a focus on U.S. market approval expected around 2028 [51][54] Financial and Strategic Partnerships - **Recent Financing**: Secured over $60 million from partners including Medtronic and Terumo, minimizing equity dilution and providing a strong balance sheet [14][15] - **Business Model**: Focused on leveraging strategic partnerships for commercialization, with significant royalty interests from products [7] Market Dynamics and Clinical Insights - **Physician Engagement**: High enthusiasm from physicians regarding the unique delivery method of Virtue and the potential clinical advantages [34] - **Clinical Data**: Ongoing education for physicians about the differences between sirolimus and paclitaxel, emphasizing the benefits of sirolimus in healing vessels [33] - **Hypertension and Heart Failure**: AVIM therapy targets a unique patient population with uncontrolled systolic hypertension, potentially impacting quality of life and cardiac function [60][63] Conclusion - **Outlook**: Orchestra BioMed is well-positioned for future growth with innovative products addressing significant market needs, strong partnerships, and a clear path towards commercialization [36][64]

Core Viewpoint - Orchestra BioMed Holdings, Inc. has successfully completed strategic transactions and equity offerings totaling an expected $111.2 million to advance its late-stage AVIM therapy and Virtue SAB clinical programs [1][2]. Financial Summary - The $111.2 million in expected gross proceeds includes $56.2 million from a public offering and private placements, with net proceeds of approximately $51.8 million after expenses [2][4]. - Medtronic and Ligand have committed a total of $55 million in royalty-based, non-dilutive investments, with Ligand contributing $35 million and Medtronic $20 million [3][4]. Use of Proceeds - The net proceeds will fund significant value-creating catalysts, including the completion of enrollment and follow-up for the BACKBEAT study and substantial enrollment of the Virtue Trial [3][5]. Clinical Programs - AVIM therapy aims to treat uncontrolled hypertension and has shown promising results in pilot studies, with reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure [9]. - Virtue SAB is designed to deliver sirolimus for treating coronary in-stent restenosis and has demonstrated positive three-year clinical data in prior studies [10]. Strategic Partnerships - The company has established collaborations with Medtronic for AVIM therapy and Terumo for Virtue SAB, enhancing its potential for successful commercialization [7]. - The partnerships reflect confidence in the transformative potential of the company's therapeutic programs [2]. Market Position - Orchestra BioMed focuses on high-impact technologies in the biomedical sector, addressing significant unmet needs in cardiovascular care [7]. - The company has received four Breakthrough Device Designations from the FDA for its core programs, indicating the high potential of its technologies [7].